Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has entered the inquiry stage for its IPO on the ChiNext board, focusing on high-performance vascular interventional medical devices [1] Company Overview - Boma Medical specializes in the research, production, and global sales of complex vascular disease interventional treatment solutions, positioning itself as a leading provider in the industry [1] - The company is also recognized as a top manufacturer in the domestic vascular interventional balloon catheter sector, both in terms of production and sales volume [1] IPO Details - The company aims to raise 1.7 billion yuan through its IPO, which will be allocated to five projects, including the establishment of a global headquarters in Songshan Lake, technological upgrades at its Hunan production base (Phase I), and research and development of interventional medical devices [1]

Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has applied for listing on the Shenzhen Stock Exchange's ChiNext board, with a fundraising target of 1.7 billion yuan, and is recognized as a leading provider of complex vascular disease intervention solutions globally [1][2]. Company Overview - Boma Medical specializes in the research, production, and global sales of high-performance vascular interventional medical devices, holding a leading position in the domestic market for vascular balloon catheters [1][2]. - The company has developed a comprehensive product matrix with over 50 product series, covering key areas such as coronary intervention, peripheral intervention, neuro intervention, blood dialysis pathways, and interventional accessories [1][2]. Research and Production - Boma Medical has established five R&D centers and laboratories globally, along with four production bases to ensure high-quality supply and scalability [1][2]. - The company has a strong focus on innovation, with significant R&D investments and a well-structured talent team, leading to multiple global breakthroughs in product technology and core processes [2]. Market Presence - The company's products are marketed in over 100 countries and regions, serving thousands of hospitals and medical centers worldwide, thereby establishing a strong brand image in the vascular interventional medical device market [2]. - Boma Medical has adopted a three-pronged business strategy of "innovation + scalability + internationalization," positioning itself as a significant player in the global vascular intervention industry [2]. Financial Performance - For the fiscal years 2022 to 2025, Boma Medical reported revenues of approximately 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan respectively, with net profits of -36.06 million yuan, 25.99 million yuan, 76.78 million yuan, and 35.65 million yuan [3][4]. - As of June 30, 2025, the total assets of the company reached approximately 1.04 billion yuan, with a debt-to-asset ratio of 35.38% [4]. Market Share - According to Frost & Sullivan, Boma Medical holds a 9.6% market share in the Chinese coronary balloon dilation catheter market, ranking fourth overall and first among domestic brands [3]. - The company also holds a 4.7% market share in the Chinese peripheral artery balloon dilation catheter market, ranking fifth [3].

Group 1: New Listings - Jiangsu Xihua New Energy Technology Co., Ltd. listed on the Shanghai Stock Exchange main board on December 23, raising 1.01 billion yuan, with a first-day stock price increase of 264.46% and a market cap of approximately 11.4 billion yuan as of December 29 [3][5] - Ningbo Jianxin Superconducting Technology Co., Ltd. listed on the Shanghai Stock Exchange Sci-Tech Innovation Board on December 24, raising 779 million yuan, with a first-day stock price increase of 212.81% and a market cap of approximately 7.9 billion yuan as of December 29 [3][5] - Shenzhen Tian Su Measurement and Testing Co., Ltd. listed on the Shenzhen Stock Exchange ChiNext on December 23, raising 600 million yuan, with a first-day stock price increase of 174.48% and a market cap of approximately 6.8 billion yuan as of December 29 [4][5] - Nabai Chuan New Energy Co., Ltd. also listed on the Shenzhen Stock Exchange ChiNext on December 23, raising 632 million yuan, with a first-day stock price increase of 408.17% and a market cap of approximately 10.1 billion yuan as of December 29 [4][5] Group 2: Companies Passing Review - Shijiazhuang Vision Technology Co., Ltd. passed the review for listing on the Shanghai Stock Exchange Sci-Tech Innovation Board on December 24, focusing on micro-display solutions [6][8] - Luoyang Shenglong Mining Group Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange main board on December 23, engaged in non-ferrous metal mining [9][10] - Hangzhou Fuen Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange main board on December 26, specializing in eco-friendly fabric [9][10] - Shenzhen Dapu Microelectronics Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange ChiNext on December 25, focusing on enterprise-level SSD products [9][10] - Nanchang Sanrui Intelligent Technology Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange ChiNext on December 26, specializing in drone and robot power systems [9][10] Group 3: Companies Submitting IPO Applications - Tianjin Fujida Bicycle Industrial Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange main board on December 24, planning to raise 773 million yuan [12][14] - Shenyang Compressor Group Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange main board on December 25, planning to raise 2.134 billion yuan [12][19] - Shenzhen Hanno Medical Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 23, planning to raise 1.062 billion yuan [12][23] - Dandong Oriental Measurement and Control Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 25, planning to raise 1.1 billion yuan [12][25] - Suzhou Tongxin Medical Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 26, planning to raise 1.064 billion yuan [12][27] - Shenzhen Deep Blue Ocean Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 26, planning to raise 1.5 billion yuan [12][29] Group 4: Financial Data Highlights - Fujida projected revenues of 4.371 billion yuan, 3.621 billion yuan, and 4.880 billion yuan from 2022 to 2024, with net profits of 348 million yuan, 285 million yuan, and 408 million yuan respectively [17][18] - Shenyang Compressor Group projected revenues of 7.396 billion yuan, 8.206 billion yuan, and 9.309 billion yuan from 2022 to 2024, with net profits of 181 million yuan, 355 million yuan, and 442 million yuan respectively [20][21] - Hanno Medical projected revenues of 0, 298 million yuan, and 493 million yuan from 2022 to 2024, with net losses of 647 million yuan, 3.41 billion yuan, and 1.83 billion yuan respectively [24] - Oriental Measurement and Control projected revenues of 603 million yuan, 521 million yuan, and 567 million yuan from 2022 to 2024, with net profits of 92.5 million yuan, 74.8 million yuan, and 73.1 million yuan respectively [26] - Tongxin Medical projected revenues of 8.611 million yuan, 50.453 million yuan, and 77.351 million yuan from 2022 to 2024, with net losses of 1.89 billion yuan, 3.06 billion yuan, and 3.72 billion yuan respectively [28]

Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has received acceptance for its IPO on the ChiNext board, focusing on high-performance vascular interventional medical devices and leading in the domestic market for vascular balloon catheters [1] Group 1: IPO and Fundraising - The company aims to raise 1.7 billion yuan through its IPO, which will be used for the global headquarters project, production base upgrades, R&D projects, marketing network construction, and working capital [1] - The total investment for the projects funded by the IPO is approximately 18.15 billion yuan, with specific allocations for each project detailed in the financial table [2] Group 2: Financial Performance - The company reported revenues of 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan over the reporting periods, with net profits of -30.26 million yuan, 28.50 million yuan, 77.44 million yuan, and 35.80 million yuan, indicating a rapid growth trend [3] - The revenue from the distribution model accounted for 89.15%, 88.38%, 90.60%, and 88.61% of total revenue during the reporting periods, highlighting the reliance on distributors [4] Group 3: R&D and Expenses - R&D expenditures for the years 2022, 2023, and 2024 were 55.76 million yuan, 60.47 million yuan, and 76.53 million yuan, totaling 193 million yuan, with R&D expenses as a percentage of revenue decreasing over time [6] - The company’s sales expenses were 41.78 million yuan, 62.80 million yuan, 86.69 million yuan, and 53.07 million yuan, with a decreasing trend in sales expenses as a percentage of revenue [8] Group 4: Market Challenges and Risks - The company faces potential challenges in international expansion due to complex trade environments and increasing policy uncertainties, particularly in Europe and Asia-Pacific regions [4] - The reliance on distributors poses risks to brand reputation and operational stability, as any misconduct by distributors could adversely affect the company [4] Group 5: Shareholder Agreements - The actual controller and major shareholders are subject to a buyback agreement, which may be triggered if the company fails to meet certain performance targets post-IPO [11] - If the IPO is unsuccessful, the buyback obligations will be reinstated, potentially requiring the actual controller to repurchase shares from investors [12]

Group 1: IPO Acceptance - Guangdong Boma Medical Technology Co., Ltd. and China Electronics Technology Group Corporation Si Yi Technology Co., Ltd. have received acceptance for their IPO applications on the ChiNext board, while Tianjin Fujida Bicycle Industrial Co., Ltd. has been accepted for its IPO application on the main board, with a total fundraising amount of approximately 3.973 billion yuan [1][5]. Group 2: Boma Medical - Boma Medical focuses on the research, production, and global sales of high-performance vascular interventional medical devices, being a leading provider of complex vascular disease interventional treatment solutions [6]. - The company plans to raise 1.7 billion yuan through its IPO, primarily for projects including the global headquarters in Songshan Lake, technological upgrades at the Hunan production base, research and development of interventional medical devices, marketing network construction, and working capital [6][8]. - Boma Medical has maintained a stable and rapid growth in both domestic and international markets, with a compound annual growth rate of 48.98% in revenue from 2022 to 2024 [6]. Group 3: Si Yi Technology - Si Yi Technology, a high-tech enterprise under China Electronics Technology Group, specializes in the research, manufacturing, and sales of electronic measurement instruments, with applications in satellite communication, navigation, radar, and education [9]. - The company aims to raise 1.5 billion yuan through its IPO, with funds allocated for projects such as the upgrade and expansion of high-end electronic measurement instrument production lines, new generation mobile communication testing research and development, and the establishment of a technology innovation center [11]. Group 4: Fujida - Fujida plans to raise 773 million yuan through its IPO, targeting investments in electric bicycles and high-end bicycle smart manufacturing projects, research and development center construction, and brand and marketing network development [12][14]. - The company has an annual production capacity of approximately 7 million units, with production bases located in Tianjin, Jiangsu, Vietnam, and Cambodia, serving well-known global brands and domestic shared bicycle operators [15]. - Fujida's revenue for the years 2022, 2023, 2024, and the first half of 2025 were 4.371 billion yuan, 3.621 billion yuan, 4.88 billion yuan, and 2.592 billion yuan, respectively, with net profits of 348 million yuan, 285 million yuan, 408 million yuan, and 195 million yuan [15].